An Open Label Trial Evaluating the Efficacy of Lacticaseibacillus Paracasei PS23 on Cognition

An Open Label Trial Evaluating the Efficacy of Lacticaseibacillus Paracasei PS23 on Cognition

This open label study aims to evaluate whether the consumption of probiotics can improve symptoms and overall quality of life in individuals experiencing cognitive decline symptoms, as well as to evaluate the effects of probiotics on blood-related biomarkers.

Lacticaseibacillus paracasei PS23 (PS23) is a specific strain of probiotic bacteria known for its potential health benefits, particularly in the context of aging and muscle health. Research suggests that it may improve cognitive function, reduce age-related muscle loss, and modulate the gut microbiota. Probiotic supplements like PS23 are being explored as potential therapeutic agents for age-related cognitive deficits. A prior study showed that PS23 supplementation delayed age-related cognitive decline in mice. Additionally, PS23 has shown antidepressant-like effects and has been found to enhance physical performance and promote muscle recovery following injury.

Inclusion Criteria:

• Adults aged 50 to 85 years who self-report experiencing signs of cognitive decline.
• No prior diagnosis of dementia or Alzheimer's disease (AD).
• Willing and able to comply with study assessments and requirements, and provide written informed consent.

Exclusion Criteria:

• Use of antibiotics or probiotic powder, capsules, or tablets within the past month.
• Currently undergoing antibiotic treatment.
• Known allergy to dairy products.
• Presence of immunodeficiency or impaired immune function.
• Diagnosis of small intestinal bacterial overgrowth (SIBO).
• Determined unsuitable by the investigator, for example, initiation of any new medication or therapy during the study period, particularly those related to memory impairment or cognitive decline.